Copertina

The Design of Large‐Scale Plasma Donation Trials

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Kecheng Li, Richard J. Cook
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Statistics in Medicine
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Variable Selection for Progressive Multistate Processes Under Intermittent Observation
di: Xianwei Li, et al.
Pubblicazione: (2025)

Variable Selection for Illness‐Death Processes Under Dual Observation Schemes
di: Xianwei Li, et al.
Pubblicazione: (2026)

Active‐Controlled Trial Design for HIV Prevention Trials With a Counterfactual Placebo
di: Fei Gao, et al.
Pubblicazione: (2025)

A Biomarker Signature‐Guided Clinical Trial Design for Precision Medicine
di: Yuan Li, et al.
Pubblicazione: (2025)

Specification of Estimands for Complex Disease Processes Using Multistate Models and Utility Functions
di: Alexandra Bühler, et al.
Pubblicazione: (2025)

Designing Stepped Wedge Cluster Randomized Trials With a Baseline Measurement of the Outcome
di: Kendra Davis‐Plourde, et al.
Pubblicazione: (2025)

Adaptive Biomarker‐Based Design for Early Phase Clinical Trials
di: Alessandra Serra, et al.
Pubblicazione: (2025)

Design and Analysis of N‐Of‐1 Trials That Incorporate Sequential Monitoring
di: Shu Jiang, et al.
Pubblicazione: (2025)

Bayesian Ordered Lattice Design for Phase I Clinical Trials
di: Gi‐Ming Wang, et al.
Pubblicazione: (2026)

Adaptive Designs in Trials With Time‐to‐Event Endpoints and Covariate Adjustment
di: Daniel Backenroth, et al.
Pubblicazione: (2026)

Preference‐Informed Cluster Randomized Design for Pragmatic Clinical Trials
di: Yuwei Cheng, et al.
Pubblicazione: (2026)

On Inclusion of Covariates in Model Based Dose Finding Clinical Trial Designs
di: Adrien Ollier, et al.
Pubblicazione: (2025)

A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials
di: Yingjie Qiu, et al.
Pubblicazione: (2026)

Confidence Intervals for Adaptive Trial Designs II : Case Study and Practical Guidance
di: David S. Robertson, et al.
Pubblicazione: (2025)

Unlocking Cognitive Analysis Potential in Alzheimer's Disease Clinical Trials: Investigating Hierarchical Linear Models for Analyzing Novel Measurement Burst Design Data
di: Guoqiao Wang, et al.
Pubblicazione: (2024)

Dose Individualization for Phase I Cancer Trials With Broadened Eligibility
di: Rebecca B. Silva, et al.
Pubblicazione: (2024)

Group Sequential Trial Design Using Stepwise Monte Carlo for Increased Flexibility and Robustness
di: Amitay Kamber, et al.
Pubblicazione: (2025)

A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
di: Moka Komaki, et al.
Pubblicazione: (2026)

A General Framework for Designing and Evaluating Active‐Controlled Trials with Non‐Inferiority Objectives
di: Antonio Olivas‐Martinez, et al.
Pubblicazione: (2026)

Causal Inference for First Non‐Fatal Events With the Competing Risk of Death: A Principal Stratification Approach
di: Jiren Sun, et al.
Pubblicazione: (2025)

Design and Analysis of Group Sequential Trials for Repeated Measurements When Pipeline Data Occurs: A Tutorial
di: Corine Baayen, et al.
Pubblicazione: (2025)

BAR12 : Bayesian Autoregressive Phase 1‐2 Design for Cell Therapy Trials With Manufacturing Changes
di: Cheng‐Han Yang, et al.
Pubblicazione: (2026)

A Generalized Phase I/II Dose Optimization Trial Design With Multi‐Categorical and Multi‐Graded Outcomes
di: Yichen Yan, et al.
Pubblicazione: (2025)

Exact Randomized Two‐Stage Phase 2 Clinical Trial Designs for Two Binary Co‐Primary Endpoints
di: Hyejung Jung, et al.
Pubblicazione: (2026)

Two‐Stage Double‐Arm Trial Optimal Design of Restricted Mean Survival Time With Sculpted Critical Region
di: Jiashan He, et al.
Pubblicazione: (2026)

Model‐Robust Standardization in Cluster‐Randomized Trials
di: Fan Li, et al.
Pubblicazione: (2025)

An Empirical Assessment of the Cost of Dichotomization of the Outcome of Clinical Trials
di: Erik W. van Zwet, et al.
Pubblicazione: (2026)

The Win Ratio Approach in Bayesian Monitoring for Two‐Arm Phase II Clinical Trial Designs With Multiple Time‐To‐Event Endpoints
di: Xinran Huang, et al.
Pubblicazione: (2024)

Analysis of Cohort Stepped Wedge Cluster‐Randomized Trials With Nonignorable Dropout via Joint Modeling
di: Alessandro Gasparini, et al.
Pubblicazione: (2025)

Futility Monitoring in Clinical Trials
di: Ana M. Ortega‐Villa, et al.
Pubblicazione: (2025)

On Anticipation Effect in Stepped Wedge Cluster Randomized Trials
di: Hao Wang, et al.
Pubblicazione: (2026)

Analysis of Stepped‐Wedge Cluster Randomized Trials: A Tutorial Using Marginal Models
di: Elizabeth L. Turner, et al.
Pubblicazione: (2026)

Optimal Control of Directional False Discovery Rates in Large‐Scale Testing
di: Guozhu Tang, et al.
Pubblicazione: (2025)

Sequential Monitoring of Covariate‐Adaptive Randomized Clinical Trials With Non‐Parametric Approaches
di: Xiaotian Chen, et al.
Pubblicazione: (2025)

A Partially Randomized Patient Preference, Sequential, Multiple‐Assignment, Randomized Trial Design Analyzed via Weighted and Replicated Frequentist and Bayesian Methods
di: Marianthie Wank, et al.
Pubblicazione: (2024)

Dynamic Borrowing From Historical Controls via the Synthetic Prior With Covariates in Randomized Clinical Trials
di: Daniel E. Schwartz, et al.
Pubblicazione: (2026)

An Overview and Recent Developments in the Analysis of Multistate Processes
di: Malka Gorfine, et al.
Pubblicazione: (2026)

A Nonparametric Global Win Probability Approach to the Analysis and Sizing of Randomized Controlled Trials With Multiple Endpoints of Different Scales and Missing Data: Beyond O'Brien–Wei–Lachin
di: Guangyong Zou, et al.
Pubblicazione: (2024)

Clinical Trial Simulation: Planning With the OCTAVE Framework, Implementation and Validation Principles
di: Kim May Lee, et al.
Pubblicazione: (2026)

Doubly Robust Estimation and Sensitivity Analysis With Outcomes Truncated by Death in Multi‐Arm Clinical Trials
di: Jiaqi Tong, et al.
Pubblicazione: (2025)